KIRKLAND, QC, Aug. 29, 2017 /CNW Telbec/ - Ortho Regenerative Technologies Inc. ("Ortho RTi" or the "Company"), an emerging Orthopaedic and Sports Medicine Technology company, today announced the appointment of François-Xavier Lacasse, Ph.D., to its senior management team in the newly created position of Vice President of Product Development.
Dr. Lacasse's mandate will be the development and execution of a comprehensive product development program for Ortho RTi's novel therapeutic tissue repair devices, including the streamlining of the Company's preclinical, chemistry, manufacturing, quality control and regulatory affairs activities.
Dr. Lacasse has an accomplished history of success in the life sciences industry and brings over 20 years of drug development experience to the Company. Prior to joining Ortho RTi, he held senior consulting and executive leaderships positions with a number of companies, including Anapharm Inc., Xanthus Life Sciences Inc., Supratek Pharma Inc., Merck Frosst and LAB Pharmaceutical Research. Dr. Lacasse holds a Ph.D. in pharmaceutical sciences from the Faculty of Pharmacy of the University of Montreal and will continue to serve as a Professor in drug development at the Faculty.
"We are very pleased to have attracted a product development executive of François-Xavier's caliber to this important new position," said Ortho RTi's Executive Chairman and CEO, Dr. Brent Norton. "I am confident that his expertise will prove to be a tremendous asset as we continue to advance our proprietary biopolymer platform."
About Ortho Regenerative Technologies Inc.
Ortho RTi is an emerging Orthopaedic and Sports Medicine technology company dedicated to the development of novel therapeutic tissue repair devices to dramatically improve the success rate of sports medicine surgeries. We are committed to improving patients' lives through increasing the success rates of surgeries for soft tissue injuries. Our proprietary biopolymer has been specifically designed to increase the healing rates of sports related injuries to ligaments, tendons and cartilage. The polymer can be directly placed into the site of injury by a surgeon during a routine operative procedure without significantly extending the time of the surgery and without further intervention. Visit us on the internet at www.orthorti.com.
This news release may contain certain forward-looking statements regarding the Corporation's expectations for future events. Such expectations are based on certain assumptions that are founded on currently available information. If these assumptions prove incorrect, actual results may differ materially from those contemplated by the forward-looking statements contained in this press release. Factors that could cause actual results to differ include, amongst others, uncertainty as to the final result and other risks. The Corporation disclaims any intention or obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events or otherwise, other than as required by security laws.
SOURCE Ortho Regenerative Technologies Inc.
For further information: Stephen Kilmer, Investor & Media Relations, 647.872.4849, [email protected]